Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (BRAVE II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03616964
Recruitment Status : Recruiting
First Posted : August 6, 2018
Last Update Posted : April 17, 2019
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 21, 2021
  Estimated Study Completion Date : May 21, 2021